U.S. Senator Maggie Hassan (D-NH) is intensifying her scrutiny of GSK Plc (NYSE:GSK) over the company's decision to pull its ...

U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline ...

Amid ongoing controversy, Sen. Maggie Hassan (D-N.H.) is investigating GSK for replacing a popular asthma inhaler with a ...

Senator Maggie Hassan is investigating GSK's discontinuation of Flovent HFA, citing increased hospitalizations, higher drug costs, and lost Medicaid rebates.

Democratic U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant ...

GSK (GSK) faces an investigation from U.S. Senator Maggie Hassan over its decision to discontinue Flovent HFA asthma inhaler last year. Read more here.

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

Democratic U.S. Senator Maggie Hassan has reportedly launched an investigation into British pharmaceutical giant GSK's (NYSE:GSK) decision to pull the branded Flovent HFA asthma inhaler from the U.S.

WASHINGTON (Reuters) -Democratic U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's decision to discontinue a widely used ...

GSK said last year it would cap out-of-pocket costs for all its inhaled asthma and chronic lung disease medicines at $35 per month for eligible patients in the United States starting January 2025 ...